Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Treviso – page 65

920 clinical trials in Treviso, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Treviso at a glance
920
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

920 trials in Treviso

Open in trial search

Study on the Effects of VS-01 for Adults with Acute-on-Chronic Liver Failure and Ascites

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Citric acid anhydrous
  • Sponsor:Versantis AG

Study of RO7247669, Tiragolumab, and Atezolizumab for Patients with Untreated Advanced Urothelial Cancer Ineligible for Platinum Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effects of GSK3915393 for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:GSK3915393
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma gastric+1

Not recruiting

Study of Pembrolizumab with Chemotherapy for Patients with Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study on Long-Term Safety and Tolerability of Iptacopan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study of Durvalumab, Tremelimumab, and Bevacizumab for Patients with Non-Resectable Liver Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Klinikum der Universitaet Muenchen AöR

Study of Durvalumab with Radiation Therapy for Patients with Early Stage Non-Small Cell Lung Cancer and Osimertinib for Those with EGFR Mutation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer After Trastuzumab Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daiichi Sankyo Inc.

Study of TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Not Undergoing Radical Cystectomy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Pfizer Inc.

Leiomyosarcoma+1

Not recruiting

Study Comparing Trabectedin and Gemcitabine for Patients with Advanced or Metastatic Leiomyosarcoma After Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Italian Sarcoma Group

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Treviso

What the registry says about research in the country

01 Hematologic Oncology

Innovative trials exploring treatments for Acute Myeloid Leukemia and Lymphomas, including studies on targeted therapies combined with standard chemotherapy. Research focuses on improving treatment outcomes for various blood cancers.

  • Gemtuzumab Ozogamicin for AML
  • Daratumumab for Plasmablastic Lymphoma
  • Follicular Lymphoma Treatment Optimization

Advanced therapeutic approaches aim to enhance minimal residual disease control and patient outcomes.

02 Gynecologic Oncology

Comprehensive research into ovarian cancer treatments, including studies of maintenance therapies and novel drug combinations. Investigations focus on both recurrent and newly diagnosed cases.

  • Olaparib Maintenance Therapy
  • Low-grade Serous Carcinoma Treatment
  • Cervical Cancer Prevention

Studies emphasize personalized treatment approaches based on specific genetic markers and disease characteristics.

03 Respiratory Medicine

Groundbreaking research in lung cancer and severe respiratory conditions, including targeted therapies for specific genetic mutations and innovative treatment combinations.

  • ALK-positive NSCLC Treatment
  • Small Cell Lung Cancer Therapy
  • Severe Asthma Management

Focus on developing personalized treatment strategies for various lung cancer subtypes and respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.